



## Laga Newsflash

### EU report reinforces competition law enforcement in the pharmaceutical industry

Ten years after its pharmaceutical sector inquiry, the European Commission ("EC") published, on 28 January 2019, a comprehensive [report on pharmaceutical competition enforcement activities](#) by both the EC and EU member states' national competition authorities ("NCAs") in the period between 2009 to 2017 (the "Report").

The Report provides a timely and in-depth analysis of anticompetitive practices within the pharmaceutical sector, amidst growing concerns about patients' access to affordable and innovative medicines. These concerns have been voiced by different stakeholders, notably national health ministries and the European Parliament.

#### Key findings

The Report singles out several types of competition concerns, in particular:

- Restrictive horizontal agreements between originators and generics such as pay-for-delay agreements;
- Outright cartels (e.g. bid rigging in hospital tenders; market sharing between pharmacies);
- Vertical agreements (e.g. clauses prohibiting distributors from promoting and selling products of competing manufacturers; parallel trade restrictions);

- Conduct that affects the incentives to innovate or hinder the entry of generics and biosimilars (through patenting, interventions before national health and medicines authorities, producing misleading information about off-label use, etc.);
- Excessive prices for medicines which amount to an abuse of dominant position;
- Preventing competition on the merits by restricting the supply of active ingredients, or by offering certain rebate and discount schemes to supply chain partners and healthcare professionals and organisations.

The Report also highlights the importance of M&A review by the EC and NCAs and possible competition concerns related to pharma deals such as harm to innovation (e.g. by acquiring competing technologies) or price increases for medicines.

Aside from direct enforcement activities, NCAs also increasingly take on more market monitoring investigations (e.g. retail and wholesale distribution of medicines; penetration of generics) and advocacy activities (e.g. ad hoc advice to lawmakers and to national health and medicines authorities).

## Next steps

The Report provides a solid basis for the EC and NCAs to continue and intensify their enforcement efforts in the pharmaceutical sector. Industry participants should thus expect no let-up in the scrutiny that the EC and NCAs already place on pharmaceutical companies when they engage in mergers and acquisitions, or in conduct that is susceptible to concerns about anti-competitive effects. The Report will also provide insights for the different NCAs when it comes to prioritising competition law investigations within the pharmaceutical industry.

## Laga can help

If you have any concerns relating to certain business practices as described in the Report, we can help by:

- Reviewing your commercial arrangements and strategies and providing practical guidance as to how to minimise any competition and regulatory law risk;
- Providing guidance on the interplay between specific life sciences-linked legislation and general competition law;
- Reviewing your compliance policies and providing refresher training;
- Responding to any information requests you may receive from the EC or any NCA; and/or
- Assisting on any investigations you may face from the EC, NCA as well as national health and medicines authorities.

If you would like to receive more EU competition and regulatory news, please [subscribe through our form](#).

**Wim Vandenberghe, Advocaat-vennoot/Avocat associé, Tel: + 32 2 800 71 01, Email: [wivandenberghe@laga.be](mailto:wivandenberghe@laga.be)**

**Hendrik Viaene, Advocaat-vennoot/Avocat associé, Tel: + 32 2 800 70 42, Email: [hviaene@laga.be](mailto:hviaene@laga.be)**



Laga  
Gateway building  
Luchthaven Brussel Nationaal 1J  
1930 Zaventem  
Belgium

A top legal practice in Belgium, Laga is a full service business law firm, highly recommended by the most authoritative legal guides. Laga comprises approximately 140 qualified lawyers, based in Brussels (Zaventem and Watermael-Boitsfort), Antwerp, Ghent and Kortrijk. Laga offers expert advice in the fields of banking & finance, commercial, corporate/M&A, employment, IT/IP, public/administrative, insolvency and reorganisations, real estate, tax law, tax and legal services for high-net-worth families and individuals (Greenille by Laga), and litigation. Where appropriate to ensure a seamless and comprehensive high-quality service, Laga lawyers work closely with financial, assurance and advisory, tax and consulting specialists, and with select EU and US law firms.

Laga provides thorough and practical solutions tailored to the needs of clients ranging from multinational companies, national large and medium-sized enterprises, financial institutions, and private clients to government bodies.

More information: [www.laga.be](http://www.laga.be)

© 2019, Laga, Belgium - The content and layout of this communication are the copyright of the law firm Laga or its contributors, and are protected under copyright and other relevant and intellectual property rights laws and regulations. No reproduction in any form or through any medium is allowed without the explicit consent of Laga or its contributors.

[Subscribe](#) | [Unsubscribe](#)